

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>FORM PTO-1449A and B (Modified)</small>				APPLICATION NO.: 09/934,249	ATTY. DOCKET NO.: P0738.70001US00
				FILING DATE: August 21, 2001	CONFIRMATION NO.: 6506
				APPLICANT: Richard T. Lee et al.	
				GROUP ART UNIT: 1648	EXAMINER: Zachariah Lucas
Sheet	1	of	3		

#### U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
32	A1	5,217,899		Shapiro, et al.	06/08/1993

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
32	C8	Arstall et al, "Human Ventricular Myocytes <i>in vitro</i> Exhibit Both Early and Delayed Preconditioning Responses to Simulated Ischemia," <i>J Mol Cell Cardiol</i> , Vol. 30, pp. 1019-25 (1998)	
32	C9	Barbee et al, "Strain measurements in cultured vascular smooth muscle cells subjected to mechanical deformation," <i>Ann Biomed Eng</i> 1994 22(1): 14-22	
32	C10	Carballo et al, "Bone Marrow Transplantation Reproduces the Tristetraprolin-Deficiency Syndrome in Recombination Activating Gene-2 (-/-) Mice," <i>J Clin Invest</i> , Vol. 100, No. 5, pp. 986-95 (1997)	
32	C11	Chen et al., "Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-hydroxyvitamin D-3," <i>Biochim Biophys Acta</i> 1219(1) 26-32, 1994	
32	C12	Cheng, et al. "Mechanical Strain Tightly Controls Fibroblast Growth Factor-2 Release From Cultured Human Vascular Smooth Muscle Cells," <i>Circ. Res.</i> 1997; 80: 28-36.	
32	C13	Cortes et al, "BTG Gene Expression in the p53-Dependent and -Independent Cellular Response to DNA Damage," <i>Molecular Carcinogenesis</i> , Vol. 27, pp. 57-64 (2000)	
32	C14	Geisterfer-Lowrance et al., "A mouse model of familial hypertrophic cardiomyopathy," <i>Science</i> 1996 272: 731-734	
32	C15	Haley et al, "Overexpression of Eotaxin and the CCR3 Receptor in Human Atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation," <i>Circulation</i> , Vol. 102, pp. 2185-2189 (2000)	
32	C16	Hamada et al, "Stretch Activates Jun N-terminal Kinase/Stress-activated Protein Kinase in Vascular Smooth Muscle Cells through Mechanisms Involving Autocrine ATP Stimulation of Purinoceptors," <i>J. Biol. Chem.</i> Vo. 273, No. 11, pp. 6334-6340 (1998)	
32	C17	Johnson et al, "Similar but distinct effects of the tristetraprolin/TIS11 immediate-early proteins on cell survival," <i>Oncogene</i> , Vol. 19, pp. 1657-1664 (2000)	
32	C18	Karas et al, "Human vascular smooth muscle cells contain functional estrogen receptor," <i>Circulation</i> 1994 89: 1943-50	
32	C19	Kaye et al, "Role of Transiently Altered Sarcolemmal Membrane Permeability and Basic Fibroblast Growth Factor Release in the Hypertrophic Response of Adult Rat Ventricular Myocytes to Increased Mechanical Activity In Vitro," <i>J Clin Invest.</i> , Vol. 97, No. 2, pp. 281-91 (1996)	
32	C20	Kobayashi et al, "Regulation of a Novel Immediate Early Response Gene, <i>IEX-1</i> , in Keratinocytes by 1 $\alpha$ , 25-Dihydroxyvitamin D <sub>3</sub> ," <i>Biochem Biophys Res Commun.</i> , Vol. 251, pp. 868-73 (1998)	


3222 2124105



FORM PTO-1449A and B (Modified)				APPLICATION NO.: 09/934,249	ATTY. DOCKET NO.: P0738.70001US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: August 21, 2001	CONFIRMATION NO.: 6506
				APPLICANT: Richard T. Lee et al.	
Sheet	2	of	3	GROUP ART UNIT: 1648	EXAMINER: Zachariah Lucas

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
32	C21	Kondratyev et al, "Identification and characterization of a radiation-inducible glycosylated human early-response gene," <i>Cancer Res</i> 1996 56(7):1498-502	
32	C22	Kumar et al, "A Novel Immediate Early Response Gene, IEX-1, Is Induced by Ultraviolet Radiation in Human Keratinocytes," <i>Biochem Biophys Res Commun.</i> , Vol. 253, pp. 336-41 (1998)	
32	C23	Lai et al, "Evidence that Tristetraprolin Binds to AU-Rich Elements and Promotes the Deadenylation and Destabilization of Tumor Necrosis Factor Alpha mRNA," <i>Mol Cell Biol</i> Vol. 19, No. 6, pp. 4311-23 (1999)	
32	C24	Laufs et al. "Neuroprotection mediated by changes in the endothelial actin cytoskeleton" <i>J. Clin. Invest.</i> , Vol. 106, No. 1, pp. 15-24 (2000)	
32	C25	Lee et al, "An equibiaxial strain system for cultured cells," <i>Am J Physiol.</i> , pp. C1400-8 (1996)	
32	C26	Nie et al, "ERF-2, the human homologue of the murine <i>Tis11d</i> early response gene," <i>Gene</i> Vol. 152, pp. 285-6 (1995)	
32	C27	Nishiyama et al. "Identification of Thioredoxin-binding Protein-2/Vitamin D <sub>3</sub> Up-regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression". <i>Journal of Biological Chemistry</i> Vol. 274, No. 31, pp. 21645-21650 (1999)	
32	C28	Saitoh et al, "Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1," <i>EMBO Journal</i> , Vo.. 17, No. 9, pp. 2596-2606 (1998)	
32	C29	Schafer et al, "The putative apoptosis inhibitor IEX-1L is a mutant nonspliced variant of p22 <sup>PRG1/IEX-1</sup> and is not expressed <i>in vivo</i> ," <i>Biochem Biophys Res Commun</i> 1999, 262(1):139-45	
32	C30	Schafer et al, "Human PACAP response 1 gene (p22/PRG1): proliferation-associated expression in pancreatic carcinoma cells," <i>Pancreas</i> 1999 18(4): 378-84	
32	C31	Schafer et al, "The promoter of human p22/PACAP response gene 1 (PRG1) contains functional binding sites for the p53 tumor suppressor and for NF <sub>κ</sub> B," <i>FEBS Lett</i> 1998 436(2): 139-43	
32	C32	Schafer et al, "PRG1: A novel early response gene transcriptionally induced by pituitary adenylate cyclase activating polypeptide in a pancreatic carcinoma cell line," <i>Cancer Res.</i> 1996 56: 2641-2648	
32	C33	Segev et al, "Müllerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NF <sub>κ</sub> B-mediated Pathway," <i>J Biol Chem.</i> , Vol. 275, No. 37, pp. 28371-28379 (2000)	
32	C34	Tagaki et al, "Expression of thioredoxin is enhanced in atherosclerotic plaques and during neointima formation in rat arteries," <i>Lab Invest</i> 1998, 78:957-96	
32	C35	Taylor et al, "A pathogenic role for TNF $\alpha$ in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency," <i>Immunity</i> 1996 May 4(5) 445-54	
32	C36	Topper et al, "Vascular MADS: Two novel MAD-related genes selectively inducible by flow in human vascular endothelium," <i>PNAS</i> , Vol. 94, pp. 9314-9319 (1997)	
32	C37	Wu et al, "IEX-1L, an apoptosis inhibitor involved in NF- $\kappa$ B-mediated cell survival," <i>Science</i> 1998 281(5379):998-1001	
32	C38	Yang et al, "Expression of a vitamin D-regulated gene (VDUP-1) in untreated and MNU-treated rat mammary tissue," <i>Breast Cancer Res Treat</i> , Vol. 48, pp. 33-44 (1998)	
32	C39	NCBI Accession No. A1761441	
32	C40	NCBI Accession No. AL12193	
32	C41	NCBI Accession No. A1594390	
32	C42	NCBI Accession No. NM_004338	
32	C43	NCBI Accession No. AQ177461	
32	C44	NCBI Accession No. AL035541	
32	C45	NCBI Accession No. X67644	
32	C46	NCBI Accession No. AF173681	
32	C47	NCBI Accession No. X77585	
32	C48	NCBI Accession No. P46694	
32	C49	NCBI Accession No. U72649	



FORM PTO-144A and B (Modified)  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Sheet 3 of 3

APPLICATION NO.: 09/934,249 ATTY. DOCKET NO.: P0738.70001US00

FILING DATE: August 21, 2001 CONFIRMATION NO.: 6506

APPLICANT: Richard T. Lee et al.

GROUP ART UNIT: 1648 EXAMINER: Zachariah Lucas

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book; magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
32	C50	NCBI Accession No. M92843	
32	C51	NCBI Accession No. S73591 (VDUP1/mRNA)	
32	C52	NCBI Accession No. S81914	
32	C53	NCBI Accession No. AF083421	
32	C54	NCBI Accession No. AF071596	
32	C55	NCBI Accession No. AF039067	
32	C56	NCBI Accession No. Y14551	
32	C57	NCBI Accession No. NP_003888	
32	C58	NCBI Accession No. P46695	
32	C59	NCBI Accession No. NM_006472	
32	C60	NCBI Accession No. NP_006463	
32	C61	NCBI Accession No. H28363	
32	C62	NCBI Accession No. H28387	
32	C63	NCBI Accession No. S73591 (MG068 homolog)	

EXAMINER	DATE CONSIDERED
<i>32</i>	2/24/05

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]